Title: Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy
| dc.contributor.author | Akash Verma | |
| dc.contributor.author | Digambar Kumar Waiker | |
| dc.contributor.author | Neha Singh | |
| dc.contributor.author | Anima Roy | |
| dc.contributor.author | Namrata Singh | |
| dc.contributor.author | Poorvi Saraf | |
| dc.contributor.author | Bhagwati Bhardwaj | |
| dc.contributor.author | Sairam Krishnamurthy | |
| dc.contributor.author | Surendra Kumar Trigun | |
| dc.contributor.author | Sushant Kumar Shrivastava | |
| dc.date.accessioned | 2026-02-09T04:33:55Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | An efficient and promising method of treating complex neurodegenerative diseases like Alzheimer’s disease (AD) is the multitarget-directed approach. Here in this work, a series of quinazoline derivatives (AV-1 to AV-21) were rationally designed, synthesized, and biologically evaluated as multitargeted directed ligands against human cholinesterase (hChE) and human β-secretase (hBACE-1) that exhibit moderate to good inhibitory effects. Compounds AV-1, AV-2, and AV-3 from the series demonstrated balanced and significant inhibition against these targets. These compounds also displayed excellent blood−brain barrier permeability via the PAMPA-BBB assay. Compound AV-2 significantly displaced propidium iodide (PI) from the acetylcholinesterase-peripheral anionic site (AChE-PAS) and was found to be non-neurotoxic at the maximum tested concentration (80 μM) against differentiated SH-SY5Y cell lines. Compound AV-2 also prevented AChE- and self-induced Aβ aggregation in the thioflavin T assay. Additionally, compound AV-2 significantly ameliorated scopolamine and Aβ-induced cognitive impairments in the in vivo behavioral Y-maze and Morris water maze studies, respectively. The ex vivo and biochemical analysis further revealed good hippocampal AChE inhibition and the antioxidant potential of the compound AV-2. Western blot and immunohistochemical (IHC) analysis of hippocampal brain revealed reduced Aβ, BACE-1, APP/Aβ, and Tau molecular protein expressions levels. The pharmacokinetic analysis of compound AV-2 demonstrated significant oral absorption with good bioavailability. The in silico molecular modeling studies of lead compound AV-2 moreover demonstrated a reasonable binding profile with AChE and BACE-1 enzymes and stable ligand−protein complexes throughout the 100 ns run. Compound AV-2 can be regarded as the lead candidate and could be explored more for AD therapy. © 2024 American Chemical Society. | |
| dc.identifier.doi | 10.1021/acschemneuro.3c00653 | |
| dc.identifier.issn | 19487193 | |
| dc.identifier.uri | https://doi.org/10.1021/acschemneuro.3c00653 | |
| dc.identifier.uri | https://dl.bhu.ac.in/bhuir/handle/123456789/48517 | |
| dc.publisher | American Chemical Society | |
| dc.subject | acetylcholinesterase | |
| dc.subject | Alzheimer’s disease | |
| dc.subject | amyloid-β | |
| dc.subject | multitargeting agents | |
| dc.subject | β-secretase | |
| dc.title | Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy | |
| dc.type | Publication | |
| dspace.entity.type | Article |
